Immune checkpoint inhibitor (ICI) therapies, such as anti‐cytotoxic T‐lymphocyte associated protein‐4, anti‐programmed cell death‐1 (anti‐PD‐1), and anti‐programmed death ligand‐1 (anti‐PD‐L1), activate the innate immune system and improve T cell anti‐tumor activity.[1, 2] ICI therapies significantly ameliorate patient survival and, therefore, have emerged as promising anti‐tumor strategies. This evidence concerns the gene CD274 and neoplasm.